To safely treat acute
 Cardiovascular diseases

at a glance

GLENZOCIMAB, A FIRST-IN-CLASS DRUG FOR CARDIOVASCULAR EMERGENCIES

Acticor Biotech is a clinical stage biopharmaceutical company, spin-off from INSERM (French National Institute of Health and Medical Research) which is developing an innovative, “first in-class” treatment for thrombotic diseases, with a primary focus on Acute Ischemic Stroke.

About Us
product & pipeline

Our drug candidate: glenzocimab

Glenzocimab is currently developed in cardiovascular emergencies and acute thrombotic diseases.

Sources

[1] Feigin, V. L., Norrving, B. & Mensah, G. A. Global burden of stroke. Circ. Res. 120, 439–448 (2017).

[2] Tarun Girotra et al., “A Contemporary and Comprehensive Analysis of the Costs of Stroke in the United States.,” Journal of the Neurological Sciences (March 15, 2020).

[3] Ramon Luengo-Fernandez et al., “Economic Burden of Stroke across Europe: A Population-Based Cost Analysis.,” European Stroke Journal (March 2020).

[4] GBD 2016 Stroke Collaborators. Global, regional and national burden of stroke, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 18, 439-458 (2019).